Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments

被引：0

作者：

Nieto Barbero, Ma Asuncion ^{[1
]}

Javier Gonzalez-Gamiz, Francisco ^{[1
]}

Jesus Rodriguez-Nieto, Ma ^{[2
]}

Sanchez, Susana ^{[3
]}

Gaudo, Javier ^{[4
]}

Valenzuela, Claudia ^{[5
]}

Lopez-Muniz, Belen ^{[6
]}

Gomez-Carrera, Luis ^{[7
]}

Laporta, Rosalia ^{[8
]}

Casanova, Alvaro ^{[9
]}

Teresa Rio, Maria ^{[10
]}

Neumomadrid, Refipimad ^{[11
]}

机构：

[1] Hosp Clin San Carlos, Madrid, Spain

[2] Fdn Jimenez Diaz, Madrid, Spain

[3] Hosp Univ Principe de Asturias, Alcaa De Henares, Spain

[4] Hosp Univ Ramon y Cajal, Madrid, Spain

[5] Hosp Univ Princesa, Madrid, Spain

[6] Hosp Univ Infanta Leonor, Madrid, Spain

[7] Hosp Univ La Paz, Madrid, Spain

[8] Hosp Univ Puerta de Hierro, Majadahonda, Spain

[9] Hosp Univ Henares, Coslada, Spain

[10] Hosp Univ Getafe, Getafe, Spain

[11] Neumomadrid, Madrid, Spain

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

Idiopathic pulmonary fibrosis; Treatments; Comorbidities;

D O I：

10.1183/13993003.congress-2019.PA1301

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA1301

引用

页数：3

共 50 条

[31] Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
de Andrade, Joao A.
Neely, Megan L.
Hellkamp, Anne S.
Culver, Daniel A.
Kim, Hyun J.
Liesching, Timothy
Lobo, Leonard J.
Ramaswamy, Murali
Safdar, Zeenat
Bender, Shaun
Conoscenti, Craig S.
Leonard, Thomas B.
Palmer, Scott M.
Snyder, Laurie D.
CLINICAL THERAPEUTICS, 2023, 45 (04) : 306 - 315
[32] Duration of Effectiveness of Antifibrotic Therapies in Patients With Idiopathic Pulmonary Fibrosis
Zheng, A.
Allison, M.
Akinniyi, A.
Zhao, S.
Montesi, S. B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[33] Racial and Ethnic Disparities in Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis
Fares, J.
Zhao, J.
George, G.
Maheu, A.
Loizidis, G.
Roman, J.
Kramer, D. R.
Li, M.
Summer, R. S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[34] Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Jieun Kang
Jin Woo Song
Scientific Reports, 11
[35] Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
Kang, Jieun
Song, Jin Woo
SCIENTIFIC REPORTS, 2021, 11 (01)
[36] Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
Zhao, Joy
Fares, Joseph
George, Gautam
Maheu, Arlene
Loizidis, Giorgos
Roman, Jesse
Kramer, Daniel
Li, Michael
Summer, Ross
RESPIROLOGY, 2023, 28 (11) : 1036 - 1042
[37] Antiinflammatory and Antifibrotic Properties of Colchicine: Implications for Idiopathic Pulmonary Fibrosis
P. Entzian
M. Schlaak
U. Seitzer
A. Bufe
Y. Acil
P. Zabel
Lung, 1997, 175 : 41 - 51
[38] Combating acute exacerbation: Methylprednisolone and antifibrotic in idiopathic pulmonary fibrosis
Abeed, Nik Nuratiqah Nik
Ng, Boon Hau
Azmel, Azat Azrai
Sharil, Nor Safiqah
Lin, Andrea Ban Yu
RESPIROLOGY, 2024, 29 : 112 - 113
[39] Antiinflammatory and antifibrotic properties of colchicine: Implications for idiopathic pulmonary fibrosis
Entzian, P
Schlaak, M
Seitzer, U
Bufe, A
Acil, Y
Zabel, P
LUNG, 1997, 175 (01) : 41 - 51
[40] Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis
Porse, Simon
Hoyer, Nils
Shaker, Saher B.
RESPIRATORY MEDICINE, 2022, 204

← 1 2 3 4 5 →